Chimerex to supply unapproved drug to try to save dying boy

|By:, SA News Editor

Chimerix (CMRX +10.5%) has agreed to provide its Brincidofovir (CMX001) treatment to a seven-year-old boy who is dying from an adenovirus infection after his immune system was weakened by a bone-marrow transplant.

Chimerex had initially refused to supply the drug, as it's not approved, but caved in after huge pressure in the media.

The company will make the boy, named Josh Hardy, the first patient in a 20-patient pilot trial, with the FDA saying it will help the firm design a Phase III study that could be launched as a continuation of the pilot. (PR)

This was corrected on 04/09/2014 at 09:39 AM. The boy's family name was incorrect.